Wolff-Parkinson-White Syndrome in a Patient with Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes Syndrome Mimicking Juvenile Myoclonic Epilepsy

No abstract available.

Lack of association between the prothrombin rs1799963 polymorphism and juvenile myoclonic epilepsy / Ausência de associação entre o polimorfismo G20210A (rs1799963) da protrombina e epilepsia mioclônica juvenil

Juvenile myoclonic epilepsy (JME) accounts for 26% of generalized idiopathic epileptic syndromes. The highest levels of thrombin activity are closely involved in the development of neurological diseases, including epilepsy. The prothrombin c.20210G>A (rs1799963) variation, which alters prothrombin mRNA stability, is associated with high plasma prothrombin levels. Objective : The present study was designed to investigate whether the SNP rs1799963 is a risk factor for JME in the northeastern Brazilian population. Results : The polymorphism was genotyped in 207 controls and 123 patients using polymerase chain reaction-restriction fragment length polymorphism method. No significant differences were observed in the genotype and allele frequencies of this polymorphism between cases and controls. Conclusion : These results present no evidence for an association of rs1799963 with JME. Further studies including other types of epilepsy are required to investigate the involvement of prothrombin gene in the genetic susceptibility to chronic seizure. .

Epilepsia mioclônica juvenil (EMJ) representa 26% das síndromes epilépticas idiopáticas generalizadas. Níveis elevados de atividade da trombina estão intimamente envolvidos no desenvolvimento de distúrbios neurológicos, incluindo epilepsia. A variante c.20210G>A (rs1799963) do gene de protrombina, que altera a estabilidade do RNAm, está associada com altos níveis de protrombina no plasma. Objetivo: Investigar se o SNP rs1799963 é um fator de risco para EMJ em uma amostra da população do nordeste brasileiro. Resultados : O polimorfismo foi genotipado em 123 pacientes e 207 controles usando a reação de polimerase em cadeia com restrição de polimorfismo. Não observamos diferença significativa nas frequências alélicas e genotípicas deste polimorfismo, entre as populações de pacientes e controle. Conclusão : Estes resultados não demonstram evidências para uma associação do polimorfismo rs1799963 com EMJ. Estudos posteriores, incluindo outros tipos de epilepsia, são necessários para investigar o envolvimento do gene protrombina na susceptibilidade genética a crises crônicas. .

Circadian rhythm and profile in patients with juvenile myoclonic epilepsy and temporal lobe epilepsy / Ritmo e perfil circadiano em pacientes com epilepsia mioclônica juvenil e epilepsia de lobo temporal

Objective This study intended to compare the circadian rhythm and circadian profile between patients with juvenile myoclonic epilepsy (JME) and patients with temporal lobe epilepsy (TLE). Method We enrolled 16 patients with JME and 37 patients with TLE from the Outpatient Clinic of UNICAMP. We applied a questionnaire about sleep-wake cycle and circadian profile. Results Fourteen (87%) out of 16 patients with JME, and 22 out of 37 (59%) patients with TLE reported that they would sleep after seizure (p < 0.05). Three (19%) patients with JME, and 17 (46%) reported to be in better state before 10:00 AM (p < 0.05). Conclusion There is no clear distinct profile and circadian pattern in patients with JME in comparison to TLE patients. However, our data suggest that most JME patients do not feel in better shape early in the day. .

Objetivo Este estudo pretende comparar o ritmo circadiano e o perfil circadiano entre pacientes com epilepsia mioclônica juvenil (EMJ) e epilepsia de lobo temporal (ELT). Método Nós entrevistamos 16 pacientes com EMJ e 37 com ELT do ambulatório da UNICAMP. Nós aplicamos um questionário sobre ciclo sono-vigília e perfil circadiano. Resultados Quatorze (87%) de 16 pacientes com EMJ e 22 de 37 (59%) pacientes com ELT relataram que eles apresentam sonolência pós-crise (p < 0,05). Três (19%) pacientes com EMJ e 17 (46%) relataram um melhor estado geral antes das 10h00min (p < 0,05). Conclusão Não há uma clara diferença de ritmo e de perfil circadiano entre pacientes com EMJ e ELT. No entanto, nossos dados sugerem que a maioria dos pacientes com EMJ não se sentem em sua melhor forma cedo pela manhã. .

Efficacy and Tolerability of Valproic Acid Once Daily Dosing for Juvenile Myoclonic Epilepsy / 대한소아신경학회지

PURPOSE: The purpose of this study was to evaluate the efficacy and tolerability of extended-release valproic acid once daily dosing in juvenile myoclonic epilepsy (JME). METHODS: Medical records of patients who received valproic acid monotherapy for the treatment of JME were retrospectively reviewed. Their clinical information regarding age, gender, seizure types, underlying neurologic status, dosing regimen, response to treatment, and adverse events related to valproic acid, were analyzed. Seizure control, compliance, and adverse events rates were compared between the group of once daily dosing and the group of twice daily dosing. RESULTS: Twenty one patients (11 boys and 10 girls) were included in the study. Twelve patients were taking valproic acid extended-release once daily and nine patients were taking twice a day. More than 50% decrease in myoclonic seizure was achieved in all the patients in both groups. Generalized tonic-clonic seizure was controlled in all the patients who were taking once daily while 3 patients (36%, 3/8 patients) in twice daily group had breakthrough generalized tonic clonic seizures during the 2 year period of treatment. However, there were no statistically significant differences in seizure control, compliance, and adverse event rates between the two groups. CONCLUSION: This study demonstrated that valproic acid extended-release once daily dosing was as effective and tolerable as twice daily in the treatment of JME. Once daily dosing of valproic acid would be convenient which improve patient compliance and consequently bring better outcome in treatment of JME.

Efficacy and Tolerability of Valproic Acid Once Daily Dosing for Juvenile Myoclonic Epilepsy / 대한소아신경학회지

PURPOSE: The aim of the this study was to verify the efficacy of the occipital nerve block (ONB) for occipital neuralgia pediatric patients who has tender point around suboccipital area. METHODS: In a retrospective way, 47 pediatric patients with occipital neuralgia were enrolled during July 2005 to July 2013. Diagnosis of occipital neuralgia is made by the International headache society criteria (2004, 2nd edition). We conducted a chart review of all the ONB performed in our clinic over 9 years. Patients were analyzed according to gender, headache type, headache duration and frequency, family history, medication history before ONB, symptoms with headache, recurrence, complications, magnetic resonance imaging scan and electroencephalogram results. Headache was measured before and after the procedure using the visual analog pain indexes. RESULTS: Forty seven (100%) patients were treated with occipital nerve block. Pain indexes were declined in 41 (87.2%) patients, but 6 (12.8%) were not response. Mean visual analog pain index scores declined by 4.7 units. Twenty five (53.2%) patients experienced recurrence of the disorder, but 14 (56.0%) patients were relived without the need for any further treatment. No complications were reported. CONCLUSION: Our data suggests that occipital nerve block was safe and effective treatment for the children with occipital neuralgia.

Epilepsia mioclônica juvenil / Juvenile myoclonic epilepsy

A epilepsia mioclônica juvenil (EMJ) foi descrita por Janz e Christian em 1957, sendo inicialmente denominada "pequeno mal impulsivo". Atualmente é considerada a mais frequente das epilepsias generalizadas idiopáticas e é caracterizada, clinicamente, por três tipos distintos de crises epiléticas: crises mioclônicas, crises tônico-clônicas generalizadas e ausências. Corresponde a uma síndrome epilética idade-relacionada, com pico entre 12 e 14 anos, comprometendo ambos os sexos de forma semelhante. É uma síndrome geneticamente heterogênea e relacionada a mutações em diversos genes, como o GABRA1 (cromossomo 5q34-q35), o CACNB4 (cromossomo 2q22-q23), o CLCN2 (cromossomo 3q26) e o EFHC1 (cromossomo 6p12-p11). Os achados eletroencefalográficos também são heterogêneos, sendo observadas descargas de espícula, polispícula, espícula-onda ou polispícula-onda em projeção generalizada. Há diversos relatos de descargas focais no EEG destes pacientes. A fisiopatogenia da EMJ permanece não totalmente esclarecida, embora mutações nos canais de cloro, disfunções talâmicas e alterações nos receptores de serotonina estejam provavelmente implicadas. Evitar fatores desencadeantes, como privação de sono, uso abusivo de álcool e/ou café, estresse físico/emocional são parte fundamental do tratamento. O valproato de sódio é a droga de primeira linha no tratamento da EMJ, embora outras drogas antiepiléticas, como o clonazepam e a lamotrigina, já se tenham mostrado eficazes. Topiramato e zonisamide são consideradas promissoras no tratamento da EMJ, enquanto carbamazepina, oxcarbazepina, fenitoína, vigabatrina e gabapentina são contraindicadas...

Gen SCN1A, Epilepsias Genéticas (Sindrome de DRAVET), Correlato Genotipo / Fenotipo / The SCN1A gene, congenital epilepsies (Dravet syndrome), genotype/phenotype correlations

Las mutaciones del Gen SCN1A están asociadas a varios síndromes epilépticos con presentaciones clínicas superpuestas y de variable severidad a saber: Epilepsia Severa Mioclonica de la Infancia o Síndrome de Dravet,Epilepsia Generalizada con Convulsiones Febriles Plus, formas más leves de Sindrome de Dravet, la Epilepsia Intratable con Convulsiones Generalizadas Tonico-Clonicas y raros casos de Migraña familiar. Todas estas formas clínicas representan el 90% de los casos de mutación del gen SCN1A; recientemente se han incluido la Epilepsia Focal y Generalizada Criptogenética, la Mioclónica–Astática, formas del Síndrome de Lennox-Gastaut y la forma severa de Epilepsia Multifocal Infantil (Epilepsia Migratoria o Multifocal Severa de la Infancia). El objetivo de la presentación de estos tres casos de Epilepsia Refractaria Precoz es enfatizar los Fenotipos variables en la evolución de la semiología convulsiva, y del compromiso cognitivo, asociado a genotipos variables (compromiso de alelos diferentes en el mismo Gen). Se debe sospechar compromiso del Gen SCN1A en toda Encefalopatía Epiléptica con convulsiones febriles de comienzo en el 1er año de vida repetidas, en muchas ocasiones, prolongadas o en ramilletes, refractarias al tratamiento médico, con neuroimagenes y EEG normales en el inicio del trastorno convulsivo aunque la regresión psicomotora ocurra años después o las mioclonias estén ausentes y en quienes la vulnerabilidad a la fiebre o a los estados infecciosos leves precipitan convulsiones

Mutations in the SCN1A gene are associated with different epi-lepsy syndromes with overlapping clinical presentations and of variable severity, such as severe myoclonic epilepsy in infancy or Dravet syndrome, generalized epilepsy with febrile seizures plus, milder forms of Dravet syndrome, refractory epilepsy with generalized tonic-clonic seizures, and rare cases of familial migraine. In 90% of all these clinical presentations SCN1A mutations are found. More recently, cryptogenic focal and ge-neralized epilepsy, myoclonic–astatic epilepsy, different types of Lennox-Gastaut syndrome, and the severe form of infantile multifocal epilepsy (migrating partial seizures or severe infanti-le multifocal epilepsy) have also been included. The aim of the presentation of these three cases of early refractory epilepsy was to emphasize the variable phenotypes in the evolution of seizure semiology and the cognitive involvement associated with variable genotypes (involvement of different alleles of the same gene). SCN1A-gene involvement should be suspected in the face of all epileptic encephalopathies...

Diagnóstico e tratamento atual das mioclonias: revisão da literatura / Current diagnosis and treatment of myoclonus: literature review

Mioclonias são movimentos involuntários de instalação súbita e de duração breve, de rara ocorrência (2%), mesmo em serviços especializados. São classificadas de acordo com a sua distribuição, origem e etiologia. O diagnóstico se baseia, fortemente, na apresentação clínica associada às alterações eletrofisiológicas. O tratamento medicamentoso deve ser orientado conforme a sua origem anatômica, destacando-se as seguintes drogas: clonazepam, levetiracetam, piracetam e valproato de sódio. A politerapia é mais eficaz do que a monoterapia, particularmente nas mioclonias de origem cortical. O objetivo desta revisão é enfatizar o diagnóstico e o tratamento atual das condições mais expressivas observadas na prática neurológica, tais como: distonia-mioclônica, mioclonia proprioespinhal, epilepsia com ausência mioclônica, síndrome de West, epilepsia mioclônica juvenil, doença por corpos de Lewy, degeneração corticobasal, panencefalite esclerosante subaguda, doença de Creutzfeldt-Jakob, síndrome de Lance-Adams, mioclonia induzida por drogas, mioclonia medular e mioclonia periférica.

Myoclonus are sudden, brief and rare abnormal movements. They can be classified according to their distribution, origin and etiology. The diagnosis is based largely on the clinical features associated with electrophysiological data. The treatment must be guided according to anatomical origin, highlighting the following drugs: clonazepam, levetiracetam, piracetam and sodium valproate. Polytherapies are more effective than monotherapy, particularly in cortical myoclonus. The aim of this review is to emphasize the current diagnosis and treatment of the more expressive morbid conditions seen in neurological practice, such as: myoclonus-dystonia, propriospinal myoclonus, epilepsy with myoclonic absences, West syndrome, juvenile myoclonic epilepsy, Lewy body disease, corticobasal degeneration, subacute sclerosing panencephalitis, Creutzfeldt-Jakob disease, Lance-Adams syndrome, drug-induced myoclonus, spinal myoclonus and peripheral myoclonus.

Calidad de vida en pacientes adolescentes con epilepsia en México / Quality of life in adolescent patients with epilepsy in Mexico

Antecedentes. La epilepsia afecta todas las áreas en la vida del niño que la padece. Hay pocos estudios al respecto en poblaciones latinoamericanas. Nuestro objetivo fue evaluar la calidad de vida de los pacientes adolescentes con epilepsia con el uso del cuestionario QOLIE-31 en un hospital de tercer nivel de atención, así como identificar los factores que influyen en la misma. Pacientes y métodos. Un total de 60 pacientes adolescentes entre 12 y 17 años de la consulta externa de neurología pediátrica del Hospital Infantil “Federico Gómez” cumplió los criterios de inclusión. Se les aplicó el cuestionario QOLIE-31 entre septiembre 2008 a mayo 2009. Resultados: El 58.3% de los pacientes reportó una mala calidad de vida y solo 6.7% muy buena calidad de vida, siendo más afectados la calidad de vida en general (98.3%) y la función cognitiva (65%). Un factor muy influyente fue el antecedente de epilepsia parcial y el uso de politerapia antiepiléptica. Conclusión. La calidad de vida en los adolescentes estudiados está muy afectada por la ocurrencia de epilepsias parciales, el inicio temprano y el uso de politerapia. Se requiere un programa de atención integral con más información sobre la enfermedad...

Epilepsia Mioclônica Juvenil: endofenótipos distintos considerando aspectos neuropsicológicos, traços de personalidade e variáveis clínicas / Juvenile Myoclonic Epilepsy: distinct phenotypes considering aspects neuropsychological, personality traits and variables clinics

INTRODUÇÃO: Estudos neuropsicológicos sugerem que indivíduos com EMJ apresentam disfunção executiva além de maior impulsividade, refletindo uma disfunção de lobo frontal. Este estudo teve como objetivos verificar: 1. o desempenho e gravidade de comprometimento das funções executivas; 2. presença de traços de personalidade impulsivos; 3. a correlação entre o desempenho nas funções cognitivas e a expressão de traços de personalidade impulsivos e; 4. se as variáveis da epilepsia se correlacionam com as disfunções executivas e a um pior controle de impulsos. MÉTODOS: Foram avaliados 42 pacientes com EMJ e 42 sujeitos saudáveis pareados por idade, escolaridade e nível socioeconômico, através de bateria compreensiva de testes neuropsicológicos avaliadores de funções executivas e questionário padronizado de avaliação de traços de personalidade (ITC). RESULTADOS: Pacientes com EMJ tiveram pior desempenho nos testes de atenção imediata, seletiva e sustentada; controle mental e inibitório; flexibilidade mental; fluência verbal; formação de conceitos e manutenção de metas. A disfunção executiva foi moderada/grave em 83,33 por cento. Pacientes com EMJ apresentaram maior expressão dos traços de personalidade impulsivos. A disfunção executiva se correlacionou com o pior controle dos impulsos. Pacientes refratários apresentaram pior disfunção executiva e maior expressão de traços impulsivos. CONCLUSÕES: Nosso estudo demonstra a presença de disfunção atencional e executiva nos pacientes com EMJ, além da presença de traços de personalidade impulsivos. Além disso, verificamos a existência de dois grupos distintos de pacientes, sendo que pacientes mais refratários apresentam-se globalmente comprometidos. Estes achados sugerem que há uma necessidade de melhor caracterização fenotípica dos pacientes com EMJ a fim de incluir endofenótipos visto que nossos resultados demonstram uma possível existência de grupos distintos de pacientes com EMJ.

INTRODUCTION: Neuropsychological studies suggest that patients with JME have executive dysfunction and impulsiveness, reflecting a possible frontal lobe dysfunction. This study aimed to verify: 1. the performance and severity of attentional and executive functions; 2. presence of impulsive personality traits; 3. correlation between cognitive performance and the expressions of impulsive personality traits; 4. correlation between epilepsy variables and neuropsychological performance as well as worse impulse control. METHODS: We evaluated 42 patients with JME and a group of 42 control subjects, matched for age, education and socioeconomic status with a comprehensive battery of neuropsychological tests of attentional and executive functions and a standardized assessment of personality traits (TCI). RESULTS: Patients with JME showed worse performance than controls on tests of attentional span, working memory, inhibitory control, concept formation, maintenance of goals, and verbal fluency. Executive dysfunction was severe/moderate in 83.33 percent. Patients with JME showed higher expression of personality traits associated with an impaired impulse control. Attentional/executive dysfunction was correlated with poor impulse control. Refractory patients had worse executive dysfunction with an even a greater presence of impulsive personality traits. CONCLUSIONS: Our study demonstrates the presence of attentional and executive dysfunction in patients with JME, as well as the presence of impulsive personality traits. We also note the existence of two distinct groups of patients, were more refractory patients appear to present broader impairment. These findings suggest that there is a need for better phenotypic characterization of patients with JME to include diverse phenotypes since our results suggest a possible existence of distinct groups of patients with JME.

Clinical efficacy and safety of lamotrigine monotherapy in newly diagnosed pediatric patients with epilepsy / 소아과

PURPOSE: To verify the efficacy and safety of lamotrigine (LTG) monotherapy in newly diagnosed children with epilepsy. METHODS: We prospectively enrolled 148 children who had undergone LTG monotherapy at our institution between September 2002 and June 2009. Twenty-nine patients were excluded: 19 due to incomplete data and 10 were lost to follow up. The data of the remaining 119 patients was analyzed. RESULTS: We enrolled 119 pediatric epilepsy patients (aged 2.8-19.3 years; 66 males and 53 females) in this study. Out of 119 patients, 29 (25.2%) had generalized epilepsy and 90 (74.8%) had partial epilepsy. The responses of seizure reduction were as follows: Seizure freedom (no seizure attack for at least 6 months) in 87/111 (78.4%, n=111) patients; partial response (reduced seizure frequency compared to baseline) in 13 (11.7%) patients; and persistent seizure in 11 (9.9%) patients. The seizure freedom rate was in 81.6% in patients with partial seizure (75.9% for complex partial seizure and 90.9% for benign rolandic epilepsy) and 44.8% in patients with generalized epilepsy (30.0% for absence seizure, 35.7% for juvenile myoclonic epilepsy patients, and 100.0% for idiopathic generalized epilepsy patients). Adverse reactions were reported in 17 (14.3%) patients, and 8 patients (6.7%) discontinued LTG because of rash and tic. No patient experienced severe adverse reaction such as Stevens-Johnson syndrome. CONCLUSION: LTG showed excellent therapeutic response and had few significant adverse effects. Our findings report may contribute in promoting the use of LTG monotherapy in epileptic children.

Adherence to treatment in patients with juvenile myoclonic epilepsy: correlation with quality of life and adverse effects of medication / Adesão ao tratamento em pacientes com Epilepsia Mioclônica Juvenil: correlação com qualidade de vida e efeitos adversos da medicação

PURPOSE: To study the adherence to clinical treatment in patients with Juvenile Myoclonic Epilepsy (JME) and its correlation to Quality of Life (QOL) scores, and antiepileptic drugs (AEDs) adverse effects. METHODS: Forty-three JME (ILAE,1989) outpatients in regular treatment were evaluated by clinical anamnesis and EEG/video-EEG at Hospital São Paulo, UNIFESP, Brazil. They answered a self-report questionnaire assessing adherence to treatment (scores 0 to 100), with higher scores meaning poorer adherence; Quality of Life in Epilepsy-31 (QOLIE-31) Brazilian validated version (scores 0 to 100), and the Adverse Events Profile (AEP), scores 19 to 76, in which scores ≥45 indicate toxicity; values less than 0.05 were considered statistically significant. RESULTS: Sixteen patients (37,2 percent) were on monotherapy, while 26 (60.4 percent) on polytherapy. Twenty-two (48 percent) had experienced a seizure in the preceding three months of the survey. Mean adherence to treatment score was 68.5. AEP scores ≤45 were observed in 38 (88.3 percent), and 29 (67.4 percent) reported spontaneous adverse effects with AEDs. The most common adverse effects were sleepiness in 11(13.8 percent), and restlessness in 7(8.8 percent).QOLIE-31 highest mean score was 79.0 (Social Function), and the lowest 33.0 (Seizure Worry). Adherence to treatment presented good correlation to better QOL scores (Pearson<0.05), while higher AEP scores indicated poorer adherence (Pearson<0.05). CONCLUSIONS: Adherence to treatment showed high correlation to better QOL. The presence of adverse effects was negatively associated with adherence.

OBJETIVOS: Este estudo teve como objetivo avaliar a adesão ao tratamento com drogas antiepilépticas (DAEs) em pacientes com Epilepsia Mioclônica Juvenil (EMJ) e correlacionar com a Qualidade de Vida (QV) e com os efeitos adversos à medicação. METODOLOGIA: A amostra foi composta de 43 pacientes com diagnóstico clínico e eletrográfico (EEG/Vídeo-EEG) de EMJ (ILAE,1989), em tratamento regular no Hospital São Paulo, UNIFESP, Brasil. Todos os pacientes responderam a um questionário de adesão ao tratamento (escores de 0-100), em que escores mais elevados evidenciavam uma pobre adesão ao tratamento. Para avaliar a QV foi utilizada a versão brasileira validada do Quality of Life in Epilepsy Inventory 31 (QOLIE-31); os efeitos adversos das DAEs foram avaliados através do Adverse Events Profile (AEP), escores de 19 a 76, no qual escores ≥45 indicam toxicidade. Foram considerados significantes os valores de p<0,05. RESULTADOS: Dezesseis pacientes (37,2 por cento) estavam em monoterapia e 26 (60,4 por cento), em politerapia; 22 (48 por cento) tiveram uma crise nos últimos três meses antes da entrevista. A média de adesão ao tratamento foi 68.5. Foram observados escores ≤45 em 38 (88.3 por cento) no AEP e 29 (67.4 por cento) apresentaram queixas espontâneas em relação ao uso das DAEs. Os efeitos adversos mais comuns foram sonolência em 11 (13,8 por cento) e inquietação em 7 (8,8 por cento). A maior média do QOLIE-31 foi 79,0 (Funcionamento Social), e a mais baixa 33,0 (Preocupação com as Crises). A adesão ao tratamento apresentou correlação estatística com valores melhores na QV enquanto valores elevados no AEP indicaram pior adesão (Pearson <0,05). CONCLUSÃO: A adesão ao tratamento mostrou alta correlação com uma melhor QV. A presença de efeitos adversos foi negativamente associada com a adesão ao tratamento.

Epilepsia mioclônica juvenil: estudo clínico, epidemiológico, terapêutico e da qualidade de vida / Juvenile myoclonic epilepsy: a clinical, epidemiological, therapeutic and quality of life study

INTRODUÇÃO: A Epilepsia Mioclônica Juvenil (EMJ) é uma epilepsia idiopática generalizada, que, apesar de descrita há mais de um século, é uma entidade clínica ainda subdiagnosticada. OBJETIVO: Apresentar o perfil clínico, epidemiológico e terapêutico de pacientes com EMJ, além de mensurar a qualidade de vida destes. METODOLOGIA: Foram avaliados dezenove pacientes com EMJ, acompanhados no Hospital Universitário da Universidade Federal de Alagoas, com o Protocolo de Consulta Clínica e o QOLIE-31 (Quality of life in epilepsy), versão brasileira. RESULTADOS: O estudo mostrou que dentre os 19 pacientes selecionados, 12 (63 por cento) eram do sexo feminino; a idade de início das crises epiléticas teve média de 12 anos (±3); a história familiar para epilepsia foi positiva 78,9 por cento dos entrevistados; todos apresentavam crises mioclônicas de predomínio matinal associadas a crises tônico-clônicas generalizadas; 14 pacientes (73,7 por cento) estavam em monoterapia, sendo 13 com o ácido valpróico. A "Pontuação Global" (Overall score) do QOLIE-31 variou de 26 a 98, com média de 62,1 (±18,4) e T-score (escore padronizado) corresponde a 47. CONCLUSÃO: A análise dos resultados auxilia sobremaneira na melhor caracterização deste grupo de pacientes, além de quantificar através de instrumento validado, pela primeira vez, a qualidade de vida destes, a qual não pode mais ser ignorada no seu manejo.

INTRODUCTION: The Juvenile Myoclonic Epilepsy (JME) is an idiopathic generalized epilepsy that, despite being descripted for more than a century, it is still a clinical entity often misdiagnosed. OBJECTIVE: Introduce the clinical, epidemiological and therapeutic profile of patients with JME, addition to measuring the quality of their life. METHODOLOGY: Nineteen patients carrying JME were evaluated. They had been examinated at the Federal University of Alagoas' Academic Hospital, with the Clinical Enquiry Protocol and the QOLIE-31 (Quality of life in epilepsy), Brasilian version. RESULTS: Among the 19 selected patients, 63 percent were female; the average age for the first seizure was twelve years (±3); the epilepsy familiar history were positive in 78,9 percent of the patients; all patients presented myoclonic seizures with matinal predominance associated to generalized tonic-clonic seizures; 14 patients (73,7 percent) were in monotherapy, 13 of these with sodium valproate. The "Overall score" of QOLIE-31 range from 26 to 98, with an average score of 62,1 (±18,4) and T-score (standardized score) corresponding 47. CONCLUSION: The analysis helps considerably in the best characterization of this group of patients and quantifies for the first time, through validated instrument, the quality of life of them, which can no longer be ignored in their management.

Espectroscopia por ressonância magnética de prótons em epilepsia mioclônica juvenil sugere o comprometimento de uma rede neuronal específica / Proton magnetic resonance spectroscopy study of juvenile myoclonic epilepsy patients suggests involvement of a specific neuronal network

OBJECTIVES: The neuroanatomical basis and the neurochemical abnormalities that underlay juvenile myoclonic epilepsy (JME) are not fully defined. While the thalamus plays a central role in synchronization of widespread regions of the cerebral cortex during a seizure, emerging evidence suggests that all cortical neurons may not be homogeneously involved. The purpose of this study was to investigate the cerebral metabolic differences between patients with JME and normal controls. METHODS: All patients had a JME diagnosis based on seizure history and semiology, EEG recording, normal magnetic resonance neuroimaging (MRI) and video-EEG. Forty JME patients (JME-P) were submitted to 1.5 T MRI proton spectroscopy (1H-MRS), multi-voxel with PRESS sequence (TR/TE = 1500/30 ms) over the following locations: prefrontal cortex (PC), frontal cortex (FC), thalamus, basal nuclei, posterior cingulate gyrus (PCG), insular, parietal and occipital cortices. We determined ratios for integral values of N-acetyl aspartate (NAA) and glutamine-glutamate (GLX) over creatine-phosphocreatine (Cr). The control group (CTL) consisted of 20 age and sex-matched healthy volunteers. RESULTS: Group analysis demonstrated a tendency for lower NAA/Cr ratio of JME-P compared to CTL predominantly on FC, PC, thalamus and occipital cortex. When compared to CTL, JME-P had a statistically significant difference in GLX/Cr on FC, PC, insula, basal nuclei, PCG and on thalamus. When evaluating the relationship among the various components of this epileptic network among JME-P, the strongest correlation occurred between thalamus and PC. Also, we found a significant negative correlation between NAA/Cr and duration of epilepsy. CONCLUSION: Reductions in NAA may represent loss or injury of neurons and/or axons, as well as metabolic dysfunction while glutamate is considered to be an excitatory neurotransmitter in the brain which is involved in the pathogenesis of epileptogenic seizures.

Longitudinal Assessment of Cognitive Function in Patients with Juvenile Myoclonic Epilepsy / 대한간질학회지

BACKGROUND AND PURPOSE: We investigated the cognitive change of patients with juvenile myoclonic epilepsy (JME) after a long-term antiepileptic drug(s) (AED) administration to clarify the cause of cognitive impairment. METHODS: Thirty-three patients with JME who were newly diagnosed or did not take any AED for at least 6 months prior to the beginning of the study were included. We conducted neuropsychological tests at baseline and after at least 12 months of AEDs trial. Forty healthy controls were acquired according to age- and education-match to patients with JME. We compared the differences of neuropsychological outcomes among them. We tried to identify the determinants for cognitive performances after AEDs trial. RESULTS: Twenty-seven patients completed the second neuropsychological tests. Seizure frequency and EEG abnormality were significantly decreased after AEDs intake. The Number of epileptiform discharges (EDs) on EEG tended to be decreased at last visit. However, cognitive performances between baseline and follow-up period were not different. Cognitive measures of baseline and follow-up period were worse than those of controls in list learning, forward digit span, backward digit span, Trail Making Test, and verbal fluency. Cognitive performances of follow-up period in the JME group were not correlated with age at seizure onset, duration of epilepsy, seizure recurrence, EEG abnormality, and type of AEDs. CONCLUSIONS: Cognitive performances of JME were not recovered to the level of healthy controls despite the control of seizures and EDs by AEDs. Therefore, cognitive impairment of JME may be due to irreversible, disease-related characteristics.

Vasodepressive Response of Head-up Tilt-Table Test in Patients With Juvenile Myoclonic Epilepsy

BACKGROUND: Juvenile myoclonic epilepsy (JME) is characterized by myoclonic seizures on awakening and giant somatosensory evoked potentials. Those characteristics suggest that JME is related with dysfunction of the brainstem reticular formation. Cardiovascular reflex is also closely related with the brainstem reticular formation, and head-up tilt-table test (HUT) is frequently employed to evaluate the cardiovascular reflex. We performed HUT to assess the cardiovascular reflex in patients with JME and syncope/presyncope. METHODS: We included 52 patients with alleged JME. HUT was performed in 20 of them with a history of presyncope or syncope. The protocol of HUT included 70 degree table tilting test and isoproterenol infusion test (1~5 microgram/min). We determined the positive responses according to the change of blood pressure and heart rate. The positive responses were classified as vasodepressive, cardioinhibitory, or mixed types. We retrospectively analyzed the clinical findings and responses of HUT. RESULTS: Syncope or presyncope occurred during the seizure-prone situation in 3 (15%), and during the syncope-prone situation in 17 (85%) patients. Fifteen (75%) patients had positive responses in HUT. The positive responses were during the baseline test in 1 (5%), during the low dose (( or = 4 microgram/min) of isoproterenol infusion in the remaining 4 (20%) patients. All the positive responses were vasodepressive type. CONCLUSIONS: In patients with JME, vasomotor reflex may be impaired. Our results suggest dysfunction of the brainstem reticular formation in JME.

Juvenile myoclonic epilepsy

Juvenile myoclonus epilepsy (JME) is a common epileptic syndrome, the etiology of which is genetically determined. Its onset occurs from 6 through 22 years of age, and affected patients present with myoclonic jerks, often associated with generalized tonic-clonic seizures - the most common association - and absence seizures. JME is non-progressive, and there are no abnormalities on clinical examination or intellectual deficits. Psychiatric disorders may coexist. Generalized polyspike-and-waves are the most characteristic electroencephalographic pattern. Usual neuroimaging studies show no abnormalities. Atypical presentations should be entertained, as they are likely to induce misdiagnosis. Prevention of precipitating factors and therapy with valproic acid (VPA) are able to control seizures in the great majority of patients. Whenever VPA is judged to be inappropriate, other antiepileptic drugs such as lamotrigine may be considered. Treatment should not be withdrawn, otherwise recurrences are frequent.

A epilepsia mioclônica juvenil é uma síndrome epiléptica comum, cuja etiologia é fundamentada na genética. Inicia-se entre 6 e 22 anos e os indivíduos apresentam mioclonias, que podem ser acompanhadas por crises tônico-clônicas generalizadas - associação mais comum - e crises de ausência. A doença não é progressiva, e não há alterações detectáveis no exame físico ou déficits intelectuais. Distúrbios psiquiátricos podem coexistir. Polipontas-ondas lentas generalizadas constituem o padrão eletrencefalográfico ictal típico. Não há anormalidades em exames de imagem convencionais. Apresentações atípicas devem ser consideradas, pois predispõem a erros de diagnóstico. A prevenção de fatores desencadeantes e o uso de ácido valpróico (VPA) controlam as crises epilépticas na grande maioria dos casos. Quando o VPA é inapropriado, outras drogas como a lamotrigina podem ser utilizadas. O tratamento não deve ser interrompido, visto que as recidivas são freqüentes.

Epilepsia mioclónica juvenil: benigna y crónica / Juvenile myoclonic epilepsy: bening and chronic

La epilepsia mioclónica juvenil representa el 4,3-10,7% de todas las epilepsias y se manifiesta en la segunda década de lavida. Es de base genética con el locus en el cromosoma 6p. El curso es benigno, no afecta el área cognitiva.El tratamiento es fármaco dependiente (crónico) y tiene períodosde remisión prolongados. Los EEG suelen presentar alteraciones persistentes. En los tres pacientes presentados la duración del tratamiento(durante el período de seguimiento) fue 11, 15 y 16 años. Las drogas de elección fueron ácido valproico y lamotrigina.Palabras clave: epilepsia mioclónica juvenil, tratamiento crónico,cognición normal.

Dom Pedro I of Brazil and IV of Portugal epilepsy and peculiar behavior

We present medical issues related to Dom Pedro de Alcântara Bragança e Bourbon (1798-1834), first Emperor of Brazil. This is made by means of narrative revision on historical facts starting from primary and secondary sources. Dom Pedro presented familiar incidence of epilepsy. His seizures were relatively benign and scattered, supposedly started at the age of 13: idiophatic epilepsy with generalized tonic-clonic seizures only or juvenile myoclonic epilepsy. He also had behavioral disorder characterized by hypersexuality, agitation and impulsiveness. It could have facilitated his opportunistic behavior necessary of daring to transgress the conservatism of the Portuguese crown, to create the constitutional monarchism in Brazil and in Portugal.

Apresentamos aspectos médicos relacionadas a Dom Pedro de Alcântara Bragança e Bourbon (1798-1834), primeiro Imperador do Brasil. Isso é feito por meio de revisão narrativa sobre fatos históricos baseados em fontes primárias ou secundárias. Dom Pedro apresentou epilepsia de incidência familiar. Suas crises eram relativamente benignas e esparsas, de início provavelmente aos 13 anos: epilepsia idiopática generalizada com crises tônico-clônicas apenas ou epilepsia mioclônica juvenil. Ele também tinha transtorno do comportamento caracterizado por hipersexualidade, agitação e impulsividade. Isso pode ter facilitado seu comportamento oportunístico necessário para ousar a transgredir o conservadorismo da coroa portuguesa e criar o monarquismo constitucional no Brasil e em Portugal.